Skip to main content
Clinical Trials/NCT06215300
NCT06215300RecruitingNot Applicable

The Effect of Polymorphism of the GUCY1A3 rs7692387 Gene on Cardiovascular Events After Coronary Artery Bypass Grafting.

Novosibirsk Scientific Research Institute for Circulatory Pathology2 sites in 1 country800 target enrollmentStarted: December 1, 2022Last updated:
Conditions

Trial Snapshot

Phase
Not Applicable
Status
Recruiting
Sponsor
Enrollment
800
Locations
2
Primary Endpoint
myocardial infarction, acute cerebrovascular accident, death from cardiovascular causes.

Study Overview

Brief Summary

Polymorphism in the GUCY1A3 gene worsens the activity of rCC, causing vasoconstriction and increased platelet aggregation. Studies have shown the association of the GUCY1A3 gene with the risk of coronary heart disease and its complications, with ischemic stroke

Detailed Description

Acetylsalicylic acid is indicated for the prevention of cardiovascular complications after CABG. Class I. The level of evidence A. ECS recommendations, Russian recommendations of cardiologists. However, the main problem of CABG remains thrombotic and thromboembolic complications in the immediate and long-term postoperative period, despite taking acetylsalicylic acid. According to various sources, the resistance to ASA among the population ranges from 5 to 45%. Resistance to ASA is primarily associated with genetic factors: the presence of polymorphisms of genes encoding platelet receptor proteins, and the functional activity of soluble guanylate cyclase (rCC), the synthesis of which is controlled by the GUCY1A3 gene. Studies have shown a link between the GUCY1A3 gene and the risk of coronary heart disease and its complications. The presence of polymorphism in the GUCY1A3 gene significantly worsens the activity of rCC, causing vasoconstriction and increased platelet aggregation. At the same time, acetylsalicylic acid cannot provide effective prevention of thrombotic and thromboembolic complications.

Study Design

Study Type
Observational
Observational Model
Cohort
Time Perspective
Prospective

Eligibility Criteria

Ages
18 Years to 90 Years (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • •Stable ischemic disease 2- 4

Exclusion Criteria

  • •the need to take any anticoagulants
  • •thrombocytopenia
  • •allergy to aspirin.

Outcomes

Primary Outcomes

myocardial infarction, acute cerebrovascular accident, death from cardiovascular causes.

Time Frame: 12 months

myocardial infarction, acute cerebrovascular accident, death from cardiovascular causes.

Secondary Outcomes

No secondary outcomes reported

Investigators

Sponsor
Novosibirsk Scientific Research Institute for Circulatory Pathology
Sponsor Class
Other
Responsible Party
Sponsor

Study Sites (2)

Loading locations...

Similar Trials